Ultimovacs ASA
Oslo Stock ExchangeTotal Valuation
Ultimovacs ASA carries a market capitalization of 70.53M, placing it among publicly traded companies globally. Its enterprise value stands at -25.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 70.53M |
| Enterprise Value | -25.11M |
Share Statistics
Ultimovacs ASA currently has 34.41M shares outstanding.
| Shares Outstanding | 34.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.08 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | -0.49 |
| P/OCF Ratio | -0.49 |
Financial Position
Ultimovacs ASA maintains a current ratio of 3.62, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.53, indicating elevated leverage, while an interest coverage ratio of -109.29 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.62 |
| Quick Ratio | 3.41 |
| Debt / Equity | 2.53 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -109.29 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -86.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -11.65M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Ultimovacs ASA's stock has declined approximately -82.62712% over the past 52 weeks. The 50-day moving average sits at 2.21, while the 200-day moving average is 3.65.
| Beta (5Y) | N/A |
| 52-Week Price Change | -82.62712% |
| 50-Day Moving Average | 2.21 |
| 200-Day Moving Average | 3.65 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -151.26M, while operating income came in at -151.26M.
| Revenue | N/A |
| Gross Profit | -2.96M |
| Operating Income | -151.26M |
| Pretax Income | -212.71M |
| Net Income | -201.06M |
| EBITDA | -151.26M |
| EBIT | -151.26M |
| Earnings Per Share (EPS) | -5.84 |
Balance Sheet
Ultimovacs ASA holds 107.37M in cash and equivalents against 2.09M in total debt, resulting in a net debt position of -107.37M. Total book value stands at -1.06B, with working capital of 82.37M providing operational flexibility.
| Cash & Cash Equivalents | 107.37M |
| Total Debt | 2.09M |
| Net Debt | -107.37M |
| Equity (Book Value) | -1.06B |
| Book Value Per Share | -30.78 |
| Working Capital | 82.37M |
Cash Flow
Ultimovacs ASA produced -163.40M in operating cash flow over the past twelve months. After subtracting -17,000.00 in capital expenditures, free cash flow totaled -163.42M - equivalent to -4.75 per share.
| Operating Cash Flow | -163.40M |
| Capital Expenditures | -17,000.00 |
| Free Cash Flow | -163.42M |
| FCF Per Share | -4.75 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 2.76 |
| FCF Yield | -203.81 |
Scores
Ultimovacs ASA posts an Altman Z-Score of -14.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -14.84 |